Myomo, Inc. (MYO) stock
Close on Nov 17, 2026Market cap $36.40MP/E –Yield –
Myomo, Inc. grew revenue 6.1% to $43.26M over the twelve months to Jun 30, 2026. Free cash flow was -$8.32M. At the latest close the market valued the company at $36.40M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $36.40M
- P/E ratio
- –
- Price to sales
- 0.84
- Price to book
- 6.24
- Dividend yield
- –
- Free cash flow yield
- -22.86%
Fundamentals
- Revenue
- $43.26M
- Net income
- -$14.51M
- EPS, diluted
- -$0.34
- Free cash flow
- -$8.32M
- Book value per share
- $0.14
- Diluted shares
- 43M
Trading
- Next earnings
- Mar 8, 2027 (estimated, after the close)
- Previous close
- $1.02
- Open
- $1.01
- Day's range
- $0.91 – $1.03
- Volume
- 438,688
- Average volume (20 days)
- 263,895
- 52-week range
- $0.60 – $1.89
- RSI (14 days)
- 32.2
- Volatility (1 year)
- 97.9%
- Relative volume
- 1.03×
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | MYO | S&P 500 | Difference | MYO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.4% | -4.0% | −19.4 pts | ||
| 3 months | -41.5% | -5.0% | −36.5 pts | ||
| Year to date | +1.0% | +8.2% | −7.3 pts | ||
| 1 year | +19.3% | +11.2% | +8.1 pts | ||
| 3 years | -68.2% | +68.5% | −136.7 pts | -31.7% | +19.0% |
| 5 years | -90.1% | +67.3% | −157.4 pts | -37.1% | +10.8% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Myomo filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Update
- Results
About Myomo
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Myomo is a wearable medical robotics company that develops and markets myoelectric-controlled upper limb orthoses, operating as a single business segment. Its core offering is the MyoPro product line, which includes custom-fabricated rigid arm braces that use non-invasive electromyography sensors to detect weak muscle signals and power movement in partially paralyzed upper limbs. The company serves adults and adolescents with neuromuscular conditions and upper limb paralysis resulting from stroke, brachial plexus injuries, spinal cord trauma, and other neurological disorders. Customers access these devices through direct billing to insurers, orthotics and prosthetics providers, and healthcare institutions.
Company profile, executives and historyMyomo stock: common questions
What is Myomo's stock price?
MYO closed at $0.92 on Nov 17, 2026, down 9.91% on the day. Over the past 52 weeks it traded between $0.60 and $1.89.
What is Myomo's market cap?
Myomo was worth $36.40M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is MYO's P/E ratio?
Myomo lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.34), so it has no meaningful P/E ratio.
How much revenue does Myomo make?
Myomo reported revenue of $43.26M for the twelve months to Jun 30, 2026, up 6.1% from a year earlier.
Does Myomo pay a dividend?
No. Myomo has not paid a cash dividend over the last twelve months.
When does Myomo report earnings next?
Myomo is expected to report Q4 FY2026 results on Mar 8, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has MYO stock performed over the past year?
Including dividends, MYO returned +19.3% over the past year, against +11.2% for the S&P 500.
How many MYO shares are sold short?
1M shares were sold short at the latest FINRA report, 3.49% of the float, or 5.8 days of average trading volume.
Who are Myomo's competitors?
Companies most similar to Myomo by business, industry and size include LFWD, APT, UTMD, ECOR, FOCL.
See a number that looks wrong?